Overview

Gender

male

Ron has brought over 30 novel life science and healthcare technologies from research to market, generating (£) billions in annual sales. Ron was formerly Managing Director of Amersham Group taking the company from a market Cap of £160m to the exit to GE for £9bn. Prior to joining Amersham, Ron worked for 22 years with the Wellcome Foundation Plc, holding Divisional Director appointments before leaving in 1990. Ron has since served as Chairman of a number of early stage companies that have achieved significant exit valuations such as Kudos Pharmaceuticals which completed a successful trade sale to Astra Zeneca and then Chairman and DxS which was acquired for by Qiagen.